Structure Therapeutics Inc. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
Structure Therapeutics Inc. (GPCR) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $12.63 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-06
- Structure Therapeutics Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $12.63M, a 68.25% increase year-over-year.
- Structure Therapeutics Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $11.64M, a 96.67% increase year-over-year.
- Structure Therapeutics Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $7.50M, a 24.44% increase year-over-year.
- Structure Therapeutics Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $7.51M, a 78.96% increase year-over-year.
- Structure Therapeutics Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $28.99M, a 54.26% increase from fiscal 2024.
- Structure Therapeutics Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $18.79M, a 129.45% increase from fiscal 2023.
- Structure Therapeutics Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $8.19M, a 225.82% increase from fiscal 2022.
- Structure Therapeutics Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $2.51M.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $12.63M 10-Q · filed 2026-08-06 | $24.27M derived: sum of 2 quarters · filed 2026-08-06 | ||
| 2026-03-31 | $11.64M 10-Q · filed 2026-08-06 | |||
| 2025-12-31 | $28.99M 10-K · filed 2026-02-26 | |||
| 2025-09-30 | $7.50M 10-Q · filed 2025-11-06 | $15.00M derived: sum of 2 quarters · filed 2026-08-06 | $20.92M derived: sum of 3 quarters · filed 2026-08-06 | |
| 2025-06-30 | $7.51M 10-Q · filed 2026-08-06 | $13.43M derived: sum of 2 quarters · filed 2026-08-06 | ||
| 2025-03-31 | $5.92M 10-Q · filed 2026-08-06 | |||
| 2024-12-31 | $18.79M 10-K · filed 2026-02-26 | |||
| 2024-09-30 | $6.02M 10-Q · filed 2025-11-06 | $10.22M derived: sum of 2 quarters · filed 2025-11-06 | $12.96M derived: sum of 3 quarters · filed 2025-11-06 | |
| 2024-06-30 | $4.20M 10-Q · filed 2025-11-06 | $6.94M derived: sum of 2 quarters · filed 2025-11-06 | ||
| 2024-03-31 | $2.74M 10-Q · filed 2025-11-06 | |||
| 2023-12-31 | $8.19M 10-K · filed 2026-02-26 | |||
| 2023-09-30 | $1.86M 10-Q · filed 2024-11-13 | $3.56M derived: sum of 2 quarters · filed 2024-11-13 | $6.09M derived: sum of 3 quarters · filed 2024-11-13 | |
| 2023-06-30 | $1.70M 10-Q · filed 2024-11-13 | $4.24M derived: sum of 2 quarters · filed 2024-11-13 | ||
| 2023-03-31 | $2.53M 10-Q · filed 2024-11-13 | |||
| 2022-12-31 | $2.51M 10-K · filed 2024-03-08 | |||
| 2022-09-30 | $628.00K 10-Q · filed 2023-11-17 | $1.27M derived: sum of 2 quarters · filed 2023-11-17 | $1.89M derived: sum of 3 quarters · filed 2023-11-17 | |
| 2022-06-30 | $643.00K 10-Q/A · filed 2023-11-17 | $1.26M derived: sum of 2 quarters · filed 2023-11-17 | ||
| 2022-03-31 | $620.00K 10-Q/A · filed 2023-11-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |